STME · XBRL financial data

StimCell Energetics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (STME's year ends in late May)

In thousands of dollars	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY25Aug 31, 2024	Q2 FY25†Nov 30, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 31, 2025	Q1 FY26Aug 31, 2025	Q2 FY26Nov 30, 2025	Q3 FY26Feb 28, 2026	Q4 FY26May 31, 2026	Q1 FY27Aug 31, 2026
Revenue	—	0	0*	—	—	—	—	—	—	—	—	—
Gross profit	0	0	—	—	—	—	—	—	—	—	—	—
Research and development	0	—	—	—	—	—	—	—	—	—	—	—
General and administrative	13	44	84*	16	23	33	141*	139	164	8	71*	67
Total operating expenses	43	58	117*	60	131	131	201*	252	293	72	209*	147
Interest expense	18	10	8*	9	9	9	11*	13	17	19	21*	23
Earnings per share, basic USD per share	0.00	0.00	—	0.00	(0.01)	(0.01)	—	(0.01)	(0.01)	0.00	—	(0.01)
Weighted average shares, basic thousands of shares	62,923	220,862	—	297,236	19,816	19,816	—	20,319	20,692	20,891	21,090*	21,141

† Share count changed about 1/15 in the period ending 2024-11-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (STME's year ends in late May)

In thousands of dollars	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY25Aug 31, 2024	Q2 FY25†Nov 30, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 31, 2025	Q1 FY26Aug 31, 2025	Q2 FY26Nov 30, 2025	Q3 FY26Feb 28, 2026	Q4 FY26May 31, 2026	Q1 FY27Aug 31, 2026
Cash and cash equivalents	23	80	43	21	34	7	15	6	46	10	3	7
Total assets	23	82	46	22	38	17	21	16	52	35	81	61
Accounts payable	648	277	289	311	316	311	322	296	324	320	356	342
Accrued liabilities	8	13	28	7	12	9	27	39	15	8	38	41
Total liabilities	2,548	792	873	931	1,021	1,087	1,268	1,410	1,595	1,713	1,893	2,032
Accumulated deficit	(10,290)	(10,170)	(10,295)	(10,362)	(10,502)	(10,642)	(10,862)	(11,127)	(11,437)	(11,527)	(11,757)	(11,926)
Total liabilities and equity	23	82	46	22	38	17	21	16	52	35	81	61
Common shares outstanding (cover page) thousands of shares	294,736	297,236	297,236	297,236	19,816	19,816	20,516	20,641	20,891	21,141	21,141	21,141

† Share count changed about 1/15 in the period ending 2024-11-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (STME's year ends in late May)

In thousands of dollars	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY25Aug 31, 2024	Q2 FY25†Nov 30, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 31, 2025	Q1 FY26Aug 31, 2025	Q2 FY26Nov 30, 2025	Q3 FY26Feb 28, 2026	Q4 FY26May 31, 2026	Q1 FY27Aug 31, 2026
Net cash from operating activities	(35)*	(38)*	(32)*	(23)	(17)*	(44)*	(58)*	(108)	(74)*	(86)*	(44)*	(109)
Proceeds from issuing equity	—	—	0*	—	—	—	0*	—	—	—	—	—
Net cash from financing activities	0*	95*	(4)*	0	30*	17*	66*	100	114*	50*	36*	113
Net change in cash	(35)*	57*	(36)*	(23)	13*	(27)*	8*	(8)	40*	(36)*	(7)*	4

† Share count changed about 1/15 in the period ending 2024-11-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Stimcell Energetics	6.9	not reported	(109)	21.1M	0.1 quarters	Q1 FY27 10-QAug 31, 2026
LogicMark	3,496	3,349	83*	899,759	—	Q2 FY26 10-QJun 30, 2026
Bluejay Diagnostics	9,599	not reported	(1,499)*	4.5M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Interpace Biosciences	2,688	9,131	98*	27.7M	—	Q2 FY26 10-QJun 30, 2026
Global Innovative Platforms	244	51	(134)*	49.8M	1.8 quarters	Q3 FY26 10-QJun 30, 2026
ENDRA Life Sciences	1,740	not reported	(928)*	1.5M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
INVO Fertility	3,733	2,175	(1,101)*	2.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Nu-Med Plus	5.4	0	1.1*	83.5M	—	Q2 FY26 10-QJun 30, 2026
Vycor Medical	159	418	(4.8)*	33.4M	32.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.